AMG 673

Drug Profile

AMG 673

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 27 Jul 2017 Amgen plans a phase I trial of AMG 673 for Acute myeloid leukaemia (Second-line therapy) in USA, Australia and Germany in August 2017 (NCT03224819)
  • 03 Jul 2017 Preclinical trials in Acute myeloid leukaemia in USA (IV) before July 2017 (NCT03224819)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top